January 20, 2010 – DiaGenic ASA (OSL:DIAG) and Ferrer inCode announced that they have signed a distribution agreement for the blood-based ADtect® test for early diagnosis of Alzheimer’s disease covering a total of 32 countries. The agreement gives Ferrer inCode, a biotech subsidiary of Grupo Ferrer Internacional, the exclusive right to sell and market ADtect® initially in Germany, Belgium, the Netherlands, Luxemburg, France, Italy, Spain and Portugal followed by Latin America.
The agreement is an important add-on to our distribution agreements for Europe. Ferrer is a strong player within the CNS field and has a large sales force in the major markets in Europe and Latin America with competence within both pharma and molecular diagnosis”... DiaGenic's Press Release -
